{"id":1292,"date":"2019-04-02T11:50:03","date_gmt":"2019-04-02T11:50:03","guid":{"rendered":"https:\/\/igemtherapeutics.com\/?p=1292"},"modified":"2019-04-02T11:50:03","modified_gmt":"2019-04-02T11:50:03","slug":"igem-therapeutics-announces-further-uk-government-funding","status":"publish","type":"post","link":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/","title":{"rendered":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2"},"content":{"rendered":"

Company receives grant from Innovate UK Biomedical Catalyst Primer Award<\/strong><\/p>\n

London, 2 April 2019 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a \u00a30.75 million grant from the UK\u2019s innovation agency, Innovate UK. IGEM Therapeutics will use the Biomedical Catalyst Primer Award to develop novel IgE antibodies targeting HER2, a commercially-validated cancer antigen expressed on a variety of tumour types including breast, ovarian and gastric cancer.<\/p>\n

Currently marketed anti-HER2 IgG antibodies are only able to treat patients with cancers expressing high levels of HER2 antigen. The majority of HER2 positive patients have cancers expressing intermediate or low levels of HER2 and cannot be treated with anti-HER2 IgG antibodies. To address this substantial unmet medical need, IGEM Therapeutics is developing novel, human IgE antibodies that bind to HER2.<\/p>\n

The epsilon constant region of IgE has evolved to fight complex, multicellular parasitic organisms resident in tissue by recruiting powerful immune effector cells such as macrophages, basophils and monocytes. IGEM Therapeutics believes that potent immune responses arising from IgE are suited to the destruction of solid tumours which also reside in tissue. Pre-clinical studies in the laboratory of IGEM Therapeutics Founder Dr Sophia Karagiannis at King\u2019s College London have demonstrated superior efficacy with a number of IgE antibodies when compared to their IgG equivalents. IGEM Therapeutics is also developing anti-cancer IgE antibodies targeting folate receptor alpha and CSPG-4.<\/p>\n

Dr Tim Wilson, Chief Executive Officer of IGEM Therapeutics, commented: \u201cIGEM Therapeutics is a pioneer in the use of IgE antibodies to treat cancer. We are very pleased to have been awarded our second grant from Innovate UK. Our goal is to harness the potency of the IgE-mediated immune response and thereby provide patients with new safe and effective treatment options for these serious diseases\u201d.<\/p>\n

About IGEM Therapeutics<\/strong><\/p>\n

IGEM Therapeutics is a UK immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer. Unlike immunoglobulin G (IgG), IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours.<\/p>\n

IGEM Therapeutics is a spin out of King\u2019s College London and has an ongoing collaboration with Dr. Sophia Karagiannis, a global leader in the understanding of IgE antibodies. The company has raised Series A finance from Epidarex Capital, ALSA Holdings and the UCL Technology Fund.<\/p>\n

About Innovate UK<\/strong><\/p>\n

Innovate UK is the UK\u2019s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit www.innovateuk.gov.uk<\/p>\n

For more information please contact:
\n<\/strong>Tim Wilson
\nChief Executive Officer
\nIGEM Therapeutics
\ntim@igemtherapeutics.com
\n+44 (0)20 3078 9675<\/p>\n

Communications advisor to IGEM Therapeutics:<\/strong>
\nSimon Conway
\nSenior Managing Director
\nFTI Consulting
\nsimon.conway@fticonsulting.com
\n+44 (0)20 3727 1000<\/p>\n","protected":false},"excerpt":{"rendered":"

Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a \u00a30.75 million grant from the UK\u2019s innovation agency, Innovate UK. IGEM Therapeutics will use the Biomedical Catalyst Primer Award […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[9],"tags":[],"acf":[],"yoast_head":"\nIGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen\" \/>\n<meta property=\"og:description\" content=\"Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a \u00a30.75 million grant from the UK\u2019s innovation agency, Innovate UK. IGEM Therapeutics will use the Biomedical Catalyst Primer Award […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\" \/>\n<meta property=\"og:site_name\" content=\"Epsilogen\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-02T11:50:03+00:00\" \/>\n<meta name=\"author\" content=\"Daniel\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniel\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\"},\"author\":{\"name\":\"Daniel\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\"},\"headline\":\"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2\",\"datePublished\":\"2019-04-02T11:50:03+00:00\",\"dateModified\":\"2019-04-02T11:50:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\"},\"wordCount\":484,\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"articleSection\":[\"Press Releases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\",\"url\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\",\"name\":\"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen\",\"isPartOf\":{\"@id\":\"https:\/\/epsilogen.com\/#website\"},\"datePublished\":\"2019-04-02T11:50:03+00:00\",\"dateModified\":\"2019-04-02T11:50:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/epsilogen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/epsilogen.com\/#website\",\"url\":\"https:\/\/epsilogen.com\/\",\"name\":\"Epsilogen\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/epsilogen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/epsilogen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/epsilogen.com\/#organization\",\"name\":\"Epsilogen\",\"url\":\"https:\/\/epsilogen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"contentUrl\":\"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg\",\"width\":267,\"height\":64,\"caption\":\"Epsilogen\"},\"image\":{\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0\",\"name\":\"Daniel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/epsilogen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g\",\"caption\":\"Daniel\"},\"sameAs\":[\"https:\/\/epsilogen.com\"],\"url\":\"https:\/\/epsilogen.com\/author\/daniel\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/","og_locale":"en_US","og_type":"article","og_title":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen","og_description":"Company receives grant from Innovate UK Biomedical Catalyst Primer Award London, 2 April 2019 \u2013 IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced the award of a \u00a30.75 million grant from the UK\u2019s innovation agency, Innovate UK. IGEM Therapeutics will use the Biomedical Catalyst Primer Award […]","og_url":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/","og_site_name":"Epsilogen","article_published_time":"2019-04-02T11:50:03+00:00","author":"Daniel","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniel","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#article","isPartOf":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/"},"author":{"name":"Daniel","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0"},"headline":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2","datePublished":"2019-04-02T11:50:03+00:00","dateModified":"2019-04-02T11:50:03+00:00","mainEntityOfPage":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/"},"wordCount":484,"publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"articleSection":["Press Releases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/","url":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/","name":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen","isPartOf":{"@id":"https:\/\/epsilogen.com\/#website"},"datePublished":"2019-04-02T11:50:03+00:00","dateModified":"2019-04-02T11:50:03+00:00","breadcrumb":{"@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/epsilogen.com\/igem-therapeutics-announces-further-uk-government-funding\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/epsilogen.com\/"},{"@type":"ListItem","position":2,"name":"IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2"}]},{"@type":"WebSite","@id":"https:\/\/epsilogen.com\/#website","url":"https:\/\/epsilogen.com\/","name":"Epsilogen","description":"","publisher":{"@id":"https:\/\/epsilogen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/epsilogen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/epsilogen.com\/#organization","name":"Epsilogen","url":"https:\/\/epsilogen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/","url":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","contentUrl":"https:\/\/epsilogen.com\/wp-content\/uploads\/2023\/07\/logo.svg","width":267,"height":64,"caption":"Epsilogen"},"image":{"@id":"https:\/\/epsilogen.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/25beed45dd34b674c4e479b4132fa3a0","name":"Daniel","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/epsilogen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/338bc7609426d1862789601c4efdafb0?s=96&d=mm&r=g","caption":"Daniel"},"sameAs":["https:\/\/epsilogen.com"],"url":"https:\/\/epsilogen.com\/author\/daniel\/"}]}},"_links":{"self":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1292"}],"collection":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/comments?post=1292"}],"version-history":[{"count":0,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/posts\/1292\/revisions"}],"wp:attachment":[{"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/media?parent=1292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/categories?post=1292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/epsilogen.com\/wp-json\/wp\/v2\/tags?post=1292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}